New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation

[1]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[2]  Jue Chen,et al.  Molecular structure of the ATP-bound, phosphorylated human CFTR , 2018, Proceedings of the National Academy of Sciences.

[3]  F. van Goor,et al.  VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.

[4]  A. Orth,et al.  Structure-guided combination therapy to potently improve the function of mutant CFTRs , 2018, Nature Medicine.

[5]  C. Bear,et al.  Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains , 2018, Molecular Pharmacology.

[6]  J. Mornon,et al.  Combining theoretical and experimental data to decipher CFTR 3D structures and functions , 2018, Cellular and Molecular Life Sciences.

[7]  M. Baaden,et al.  Holding the Nucleosome Together: A Quantitative Description of the DNA-Histone Interface in Solution. , 2018, Journal of chemical theory and computation.

[8]  J. Jais,et al.  Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators , 2017, Scientific Reports.

[9]  Zhengrong Yang,et al.  Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface , 2017, Molecular Pharmacology.

[10]  P. Palange,et al.  Cystic fibrosis , 2016, The Lancet.

[11]  Garry R. Cutting,et al.  From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations , 2016, Molecular biology of the cell.

[12]  J. Forman-Kay,et al.  Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy , 2016, Protein science : a publication of the Protein Society.

[13]  Alexander D. MacKerell,et al.  CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.

[14]  I. Sermet-Gaudelus,et al.  An unexpected effect of TNF-α on F508del-CFTR maturation and function , 2015, F1000Research.

[15]  B. Joris,et al.  5'-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling. , 2015, Organic & biomolecular chemistry.

[16]  S. Jonić,et al.  Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics , 2015, Cellular and Molecular Life Sciences.

[17]  Zhengrong Yang,et al.  Restoration of NBD1 thermal stability is necessary and sufficient to correct ∆F508 CFTR folding and assembly. , 2015, Journal of molecular biology.

[18]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[19]  I. Sermet-Gaudelus,et al.  Biosynthesis of cystic fibrosis transmembrane conductance regulator. , 2014, The international journal of biochemistry & cell biology.

[20]  Hong Yu Ren,et al.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.

[21]  Piotr Zielenkiewicz,et al.  Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain , 2013, EMBO molecular medicine.

[22]  Marisa Sousa,et al.  Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. , 2013, Chemistry & biology.

[23]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[24]  J. Riordan,et al.  Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[26]  Pradeep Kota,et al.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. , 2012, Journal of molecular biology.

[27]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[28]  K. Du,et al.  Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function , 2012, Cell.

[29]  Philip J. Thomas,et al.  Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences , 2012, Cell.

[30]  Alexander D. MacKerell,et al.  Optimization of the CHARMM additive force field for DNA: Improved treatment of the BI/BII conformational equilibrium. , 2012, Journal of chemical theory and computation.

[31]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[32]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[33]  Alexandre G. de Brevern,et al.  Comparative Analysis of Threshold and Tessellation Methods for Determining Protein Contacts , 2011, J. Chem. Inf. Model..

[34]  Zhengrong Yang,et al.  Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1 , 2010, Protein science : a publication of the Protein Society.

[35]  H. Senderowitz,et al.  The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis* , 2010, The Journal of Biological Chemistry.

[36]  Alexander D. MacKerell,et al.  Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.

[37]  Alexandre G. de Brevern,et al.  A Novel Evaluation of Residue and Protein Volumes by Means of Laguerre Tessellation , 2010, J. Chem. Inf. Model..

[38]  S. Freedman,et al.  Cystic fibrosis , 2009, The Lancet.

[39]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[40]  P. Zielenkiewicz,et al.  DeltaF508 mutation increases conformational flexibility of CFTR protein. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[41]  M. Amaral,et al.  Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. , 2008, Chemistry & biology.

[42]  Paola Vergani,et al.  The ABC protein turned chloride channel whose failure causes cystic fibrosis , 2006, Nature.

[43]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[44]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[45]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[46]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[47]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[48]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[49]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.